Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 43 peer-reviewed journal articles Updated
Hematology · GGCX-Related Vitamin K-Dependent Coagulation Factor Deficiency

GGCX-Related Vitamin K-Dependent Coagulation Factor Deficiency (VKCFD1): A Patient Guide

At a Glance

GGCX-related VKCFD1 is an inherited disorder that can cause abnormal bleeding along with loose or wrinkled skin and angioid streaks in the eyes. Specialist-prescribed vitamin K may improve clotting, but skin and eye changes need ongoing hematology, dermatology, and ophthalmology care.

GGCX-related vitamin K-dependent coagulation factor deficiency (VKCFD1), also referred to as GGCX-related PXE-like syndrome, is an ultra-rare genetic condition that affects two vital systems in your body simultaneously. It is caused by having two pathogenic (disease-causing) copies of the GGCX gene, which normally provides instructions for an enzyme that acts as a “finishing tool” for certain proteins [1]. Because this enzyme is responsible for activating both proteins that help your blood clot and proteins that keep your connective tissues healthy, the condition presents a dual challenge: managing a tendency toward bleeding while monitoring changes in your skin and eyes [2][3].

The first part of this condition, the bleeding phenotype, occurs because your liver cannot properly “finish” essential clotting factors (specifically Factors II, VII, IX, and X) [2]. Without these active proteins, your blood takes longer to clot, which can lead to easy bruising, frequent nosebleeds, or significant bleeding after a minor injury or surgery [4]. While many bleeding events are manageable, severe internal bleeding—such as in the brain or digestive tract—is a medical emergency that requires immediate intervention at an emergency department [5][6].

The second part of the condition involves your connective tissues and is often described as “PXE-like” because it resembles a disorder called classic Pseudoxanthoma Elasticum (PXE). In your body, the under-functioning GGCX enzyme fails to fully activate a “shield” protein (Matrix Gla Protein) that normally prevents minerals from building up in places they don’t belong [7]. Over time, this buildup can cause your skin to become loose or wrinkled, particularly around the neck and underarms, and can lead to small streaks in the back of your eyes called angioid streaks [3][8]. These skin and eye changes often progress slowly as you age [9].

Living with this condition typically centers on specialist-prescribed Vitamin K therapy. For many people, oral vitamin K can help the sluggish GGCX enzyme work better, improving the blood’s ability to clot [4]. However, because the enzyme treats clotting proteins and skin proteins differently, Vitamin K may not always stop or reverse the skin and eye manifestations [10][11]. Because the evidence base is small and limited largely to case reports, there is no universally established dose or predictable outcome. Prognosis is variable and requires a multidisciplinary care team—including a hematologist, a dermatologist, and an ophthalmologist—who can monitor all aspects of the disease and coordinate your individually tailored treatment [12][9].

In this guide

6 chapters

01

Starting Your Journey with GGCX-Related Disorders

Learn how GGCX-related disorders affect blood clotting, skin, and eyes, including vitamin K treatment, genetic inheritance, testing limits, and specialist care.

02

Recognizing Symptoms and Emergency Signs

Learn the bleeding, skin, and eye symptoms of GGCX-related disorder, including emergency warning signs, head injury risks, and when to seek urgent care.

03

The Biology of GGCX: Your Body's 'Finishing Tool'

Learn how GGCX-related disorder affects vitamin K, clotting, and connective tissue, including why skin or eye changes may persist when treatment improves bleeding.

04

Getting a Clear Diagnosis: Tests and Labs

Learn how GGCX-related disorder is diagnosed with clotting tests, factor levels, vitamin K studies, skin biopsy findings, and biallelic genetic confirmation.

05

Managing Your Care: Treatment and Prevention

Learn how GGCX-related disorder is managed with vitamin K, factor replacement for bleeding or surgery, medication safety, and lifelong eye and skin monitoring.

06

Building Your Care Team and Preparing for Visits

Learn how to build a GGCX-related disorder care team, prepare for visits, organize records, and plan for bleeding emergencies, procedures, and daily safety.

Common questions in this guide

What is GGCX-related VKCFD1?
GGCX-related VKCFD1 is an ultra-rare inherited disorder caused by disease-causing changes in both copies of the GGCX gene. The resulting enzyme problem can affect blood clotting and connective-tissue proteins, leading to bleeding problems and changes in the skin and eyes.
How can VKCFD1 affect bleeding?
It can make the blood take longer to clot, causing easy bruising, frequent nosebleeds, or prolonged bleeding after an injury or surgery. Suspected severe internal bleeding, including bleeding in the brain or digestive tract, is an emergency requiring immediate evaluation in an emergency department.
Why can VKCFD1 cause loose skin and angioid streaks?
When GGCX does not activate a protective connective-tissue protein well, minerals can build up in tissues. This may lead to loose or wrinkled skin, especially around the neck and underarms, and angioid streaks in the back of the eyes.
Can vitamin K treat GGCX-related VKCFD1?
Specialist-prescribed oral vitamin K may help the under-functioning GGCX enzyme work better and improve blood clotting. It may not prevent or reverse the skin and eye changes, and the best dose and response vary because evidence is limited.
Which specialists should manage VKCFD1?
Care is usually coordinated among a hematologist, dermatologist, and ophthalmologist. They can monitor clotting-factor levels, bleeding risk, skin changes, and eye findings and tailor follow-up or treatment to your needs.
What should I plan for an emergency or surgery with VKCFD1?
An individualized factor replacement plan may be needed for surgery or a serious bleeding event. Because severe internal bleeding can be life-threatening, it requires immediate evaluation in an emergency department.

Get notified when new evidence is published on Body skin hyperlaxity due to vitamin K-dependent coagulation factor deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Vitamin K-Dependent Protein Activation: Normal Gamma-Glutamyl Carboxylation and Disruption in Disease.

    Berkner KL, Runge KW

    International journal of molecular sciences 2022; (23(10)) doi:10.3390/ijms23105759.

    PMID: 35628569
  2. 2

    Clinical, Laboratory, and Molecular Characteristics of Inherited Vitamin K-Dependent Coagulation Factors Deficiency.

    Perrone S, Raso S, Napolitano M

    Seminars in thrombosis and hemostasis 2025; (51(2)):170-179 doi:10.1055/s-0044-1792031.

    PMID: 39496305
  3. 3

    [Pseudoxanthoma elasticum-like disease with deficiency of vitamin K-dependent clotting factors and cutis laxa features].

    Gusdorf L, Mitcov M, Maradeix S, et al.

    Annales de dermatologie et de venereologie 2016; (143(4)):279-83.

    PMID: 26944767
  4. 4

    GGCX mutations show different responses to vitamin K thereby determining the severity of the hemorrhagic phenotype in VKCFD1 patients.

    Ghosh S, Kraus K, Biswas A, et al.

    Journal of thrombosis and haemostasis : JTH 2021; (19(6)):1412-1424 doi:10.1111/jth.15238.

    PMID: 33590680
  5. 5

    Hereditary Combined Deficiency of the Vitamin K-Dependent Coagulation Factors.

    Raharimanana A, Cunat S, Falaise C, et al.

    Hamostaseologie 2025; (45(5)):396-404 doi:10.1055/a-2567-3567.

    PMID: 40541254
  6. 6

    Familial vitamin K metabolism deficiency responsible for a congenital binder phenotype.

    Grammatopoulos K, Harroche A, Peduto C, et al.

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2025; (32(6)):420-422 doi:10.1016/j.arcped.2025.05.003.

    PMID: 40562611
  7. 7

    Calcification in dermal fibroblasts from a patient with GGCX syndrome accompanied by upregulation of osteogenic molecules.

    Okubo Y, Masuyama R, Iwanaga A, et al.

    PloS one 2017; (12(5)):e0177375 doi:10.1371/journal.pone.0177375.

    PMID: 28494010
  8. 8

    GGCX mutations in a patient with overlapping pseudoxanthoma elasticum/cutis laxa-like phenotype.

    Li D, Ryu E, Saeidian AH, et al.

    The British journal of dermatology 2021; (184(6)):1170-1174 doi:10.1111/bjd.19576.

    PMID: 33000479
  9. 9

    GGCX-Associated Phenotypes: An Overview in Search of Genotype-Phenotype Correlations.

    De Vilder EY, Debacker J, Vanakker OM

    International journal of molecular sciences 2017; (18(2)) doi:10.3390/ijms18020240.

    PMID: 28125048
  10. 10

    Molecular insights into the comorbidity of vitamin K-dependent clotting factor deficiency and chondrodysplasia punctata.

    Jin DY, Chen X, Wang M, et al.

    Journal of thrombosis and haemostasis : JTH 2025; (23(12)):3832-3844 doi:10.1016/j.jtha.2025.08.011.

    PMID: 40876756
  11. 11

    Characterization of vitamin K-dependent carboxylase mutations that cause bleeding and nonbleeding disorders.

    Tie JK, Carneiro JD, Jin DY, et al.

    Blood 2016; (127(15)):1847-55 doi:10.1182/blood-2015-10-677633.

    PMID: 26758921
  12. 12

    [Partial research progress of GGCX pathogenic variation associated phenotypes].

    Shen G, Liu H, Shen Y, Xi S

    Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2022; (39(6)):646-650 doi:10.3760/cma.j.cn511374-20210430-00381.

    PMID: 35773773

This page is for informational purposes only and does not constitute medical advice. Your hematologist, dermatologist, and ophthalmologist can interpret your GGCX-related VKCFD1 findings and tailor monitoring and treatment to your situation.